The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
The challenges that adolescents and young adults (AYAs) face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, who presented findings on the different outcomes between children and AYAs with acute lymphoblastic leukemia (ALL) at the 59th American Society of Hematology Annual Meeting.
Transcript
How does social support play a role in outcomes among adolescents and young adults with ALL?
It’s not something that we looked at specifically in terms of social support but I think that it really is important when we look at the fact we saw that the duration of treatment, the length of maintenance treatment is really important. We know that these patients are in a really volatile time in their lives. Everyone comes in with a lot of important things happening in their life and that has been disrupted and so others have shown how important social support is and we’ve shown the importance of the duration of treatment. So together I think that just means that making sure we are paying attention to the social needs of these patients is crucial.
What are the unique challenges facing AYAs after treatment?
There are so many challenges that these patients face that are unique and I think that people are really working hard to try to figure out what we can do to help them. But I think the minute they walk into the door, thinking of them as a unique group of patients is the first thing we can do and just recognizing that their lives have been disrupted in a way that younger patients and older patients don’t experience and trying to understand that unique patient’s needs.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More